Human immunodeficiency virus (HIV) infection selectively targets the basal ganglia region of the brain resulting in loss of dopaminergic neurons, that have been implicated in the clinical manifestation of HIV-1-associated dementia (HAD). 1, 2 Accordingly, mounting evidence on the involvement of dopamine impairment in HAD comes from case studies on pathological specimens of HIV-infected patients demonstrating loss of dopaminergic neurons. 1 Furthermore, experimental studies have also indicated that nigrostriatal neurons in the basal ganglia are susceptible to HIV-1 protein-mediated toxicity. 3 As there is no evidence of direct infection of neurons by HIV-1, it is hypothesized that neuronal cell death is a consequence of the toxic effects of viral and cellular neurotoxins that are released from virus-infected and/or activated cells. 4 One of the potent viral toxins implicated in neuronal injury/death is the virus transactivator protein, HIV-1 Tat that can be secreted from infected cells and can be taken up by the neighboring noninfected cells, including neurons. 5 Indeed, HIV-1 Tat is known to inhibit tyrosine hydroxylase (TH) gene expression in dopaminergic neuronal cells thereby contributing to motor abnormalities observed in HAD patients. 3, 6 Neuronal homeostasis is maintained by the fine balance between neurotrophic versus neurotoxic factors. Various neurotrophic factors, such as brain-derived neurotrophic factor, nerve growth factor, and glial cell line-derived neurotrophic factor have been implicated in the protection of neurons against neurotoxins. [7] [8] [9] In this study, we explored the role of yet another neurotrophic factor, platelet-derived growth factor (PDGF) that has been documented to be critical for the development of brains of postnatal rats. 10 PDGF belongs to a family of five dimeric ligands (PDGF-AA, -AB, -BB, -CC, and -DD) assembled from four gene products (PDGF-A-D) that act via two classical receptors tyrosine kinases (RTKs), PDGF-a receptor (PDGF-aR), and PDGF-b receptor (PDGF-bR). PDGF-bR has been implicated in neuroprotection following ischemic events in the rat. 11 Members of the PDGF family have multiple roles during embryogenesis and in a variety of pathological situations in the adult. 12 Among these members, PDGF has been shown to protect primary hippocampal neurons against glutamate-induced neuronal damage. 13 In our previous findings we have reported that PDGF can exert neuroprotection against the HIV envelope protein-mediated toxicity in SH-SY5Y cells. 14, 15 PDGF-bR is known to be expressed in 90% of TH-positive neurons and has been shown to be involved in TH gene expression and neuronal survival. 16 However, whether PDGF can regulate dopaminergic neurons against HIV protein toxicity remains to be explored.
Neurotrophic family of growth factors is known to be essential for the survival of neurons. 7 The mechanism of action of the neurotrophins on neuron survival is mediated by the extracellular signal-regulated protein kinase (ERK)/cAMPresponse element-binding protein (CREB) and phosphoinositide-3-kinase (PI3K)/Akt pathways. In addition, receptors for the neurotrophins, RTKs, that can stimulate PLC-g to activate transient receptor potential canonical channels (TRPC), have also been shown to have a role in neuroprotection. 17 Recent studies have revealed these TRPC channels to be Ca 2 þpermeable, nonselective cation channels. 17 Transient receptor potential (TRP) channels are formed by homomeric or heteromeric complexes of TRP proteins that constitute at least six subfamilies: TRPC (TRP-canonical), TRP-vanilloid, TRPM (TRP-melastatin), TRP-mucolipins, TRPPs (TRPpolycystins), and TRPA1 (TRP-ankyrin transmembrane protien1). [18] [19] [20] These channels are important in various physiological processes ranging from sensation to male fertility. PDGF receptor belongs to RTKs, and the mammalian TRPC channels can be activated by RTKs. 18, 21, 22 We thus sought to examine whether TRPC channels were involved in regulating neuronal protection mediated by PDGF and, if so, what were the downstream effectors for TRPC channel activation.
In this study we show direct evidence of the neuroprotective action of PDGF against HIV Tat toxicity through two distinct signaling pathways-TRPC/Ca 2 þ /ERK and PI3K/Akt. Our data support the possibility that PDGF signaling in the midbrain neurons may contribute to the maintenance of neuronal survival.
Results
PDGF attenuates HIV-1 Tat cytotoxicity in rat primary midbrain neurons. To examine whether PDGF could abrogate Tat cytotoxicity, rat primary midbrain neurons were first exposed to HIV Tat protein (14 nM) for 24 h and cell viability assessed by [3(4,5-dimethylthiazol-2-yl)-2.5 diphenyltetrazolium bromide] (MTT) assay. As shown in Figure 1a , Tat exposure resulted in a decrease in cell viability (32%; Po0.001). Treatment of neuronal cells with either the heat-inactivated or mutant Tat, however, did not exert any cytotoxicity in these cells. We next sought to examine the neuroprotective effect of PDGF against Tat toxicity. Rat neurons were pre-treated with PDGF (20 ng/ml; concentration pre-determined based upon our previous work 14, 15 ) for 30 min followed by exposure of cells to Tat protein (14 nM). Twenty-four hours later cell viability was measured using the MTT assay. As shown in Figure 1b , pretreatment of cells with PDGF followed by exposure to HIV Tat resulted in increase in cell viability. PDGF alone did increase cell viability, although this effect was not statistically significant compared with control. These findings were also confirmed by an immunostaining assay using the antimicrotubule-associated protein-2 (MAP-2) antibody. As shown in Figures 1c and d there was loss of neuronal processes as well as MAP-2 immunoreactivity in the Tattreated group, an effect that was ameliorated by pretreatment of cells with PDGF. Cells cultured in the presence of PDGF alone did not demonstrate any change in dendrite length compared with the untreated control cells.
In addition to MAP-2 staining the neuroprotective effects of PDGF were further corroborated by morphological analysis of dopaminergic neurons following immunocytochemical staining of the cells with TH, a characteristic marker of these neurons. As shown in Figure 1e and f, treatment of neuronal cells with HIV-1 Tat resulted in B40% decrease in the total dendrite length per TH-immunoreactive neuron, pre-treatment of neuronal cultures with PDGF resulted in enhanced TH-immunoreactivity (red fluorescence).
As HIV Tat mediates neurotoxicity by the programmed cell death pathway, we next sought to examine whether PDGF-mediated protection of neurons involved inhibition of Tat-induced neuronal apoptosis using Annexin-V binding and propidium iodide uptake. As shown in Figure 1g , there was an increase in Annexin-V-positive cells (27.5 versus 15.2%) in Tat-treated cultures compared with control cells as evidenced by flow cytometry. In contrast, PDGF pre-treatment before Tat exposure resulted in decreased numbers of apoptotic cells (27.5 versus 20.9% -Tat treated versus PDGF/Tat). The above findings were further confirmed by staining cells with Hoechst 33342, a nuclear dye that stains nuclei. Pretreatment of neurons with PDGF reduced Tat-induced neuronal apoptosis as quantified in Figure 1h .
PDGF receptor is necessary for PDGF-mediated neuroprotection. As PDGF mediates signaling through its cognate receptor PDGF-bR, we next sought to examine the expression and phosphorylation pattern of this receptor in rat primary neurons. As shown in Figure 2a , rat primary midbrain neurons expressed PDGF-bR, which was rapidly phosphorylated by treatment of neurons with PDGF as evidenced by western blot analysis. Furthermore, pretreatment of cells with the PDGF receptor antagonist STI-571 (1 mM) for 1 h abolished this effect.
We next assessed whether the protective effects of PDGF were mediated via its binding to its cognate PDGF-bR. As shown in Figure 2b receptor tyrosine kinase antagonist STI-571 was able to inhibit PDGF-mediated neuroprotection in rat primary neurons, although not to that of levels with HIV Tat alone. Exposure of neurons to PDGF alone did increase cell viability, although this effect was not statistically significant. In the presence of STI-571, PDGF-mediated increase in cell viability was significantly inhibited. We acknowledge the fact that STI-571 is not a specific antagonist for PDGF-bR, because it is also known to inhibit, PDGF-aR, as well as other kinase activities. Hence as an alternative approach we next sought to knock down PDGF-bR expression in neurons using the short-interfering (si) RNA strategy. As shown in Figure 2c , PDGF-bR short-interfering RNAs (siRNA) abrogated the expression of PDGF-bR in neurons, whereas also blocking the neuroprotection mediated by PDGF ( Figure 2d ), thus confirming the role of PDGF-bR in this process.
TRPC channels are required for PDGF-mediated neuroprotection. Because Ca 2 þ is known to mediate cell survival and TRPC is a member of TRP superfamily that functions as Ca 2 þ influx channels, it is possible that Ca 2 þ influx through TRPC channels is required for the neuroprotection mediated by PDGF in primary midbrain neurons. To test this hypothesis, cells were pre-treated with TRP channel blocker and assessed for PDGF-mediated protection against Tat toxicity. As shown in Figure 3a , in neurons pre-treated with the SKF96365 (20 mM), a nonspecific inhibitor of store-operated Ca 2 þ entry and TRP channels, 23, 24 PDGF-mediated neuroprotection against Tat toxicity was inhibited compared with cells not treated with the inhibitor.
In our previous study we have demonstrated that rat primary midbrain neurons express TRPC1, 5 and 6 protein. 25 To ascertain the TRPC subtype(s) critical for PDGF-mediated neuroprotection, each of the TRPC subtypes (1, 5 or 6) was individually downregulated using the specific siRNAs, followed by assessment of PDGF-induced neuroprotection. As shown in Figure 3b siRNA against TRPC1, 5 and 6 suppressed expression of TRPC 1, 5 and 6, respectively. Interestingly however, TRPC 5 and 6 siRNAs, but not TRPC 1 siRNA alleviated PDGF-mediated neuroprotection ( Figure 3c ). These findings thus underpin the roles of TRPC 5 & 6 in neuroprotection exerted by PDGF. To further examine the role of TRPC 5 and 6 in PDGF-mediated neuroprotection, we next sought to determine whether TRPC5 and TRPC 6 colocalized with PDGF-bR in primary midbrain neurons. As shown in Figure 3d , both the TRPC channels co-localized with the PDGF-bR in these cells, thus further validating the role of these channels.
PDGF activates its receptor and stimulates phospholipase C (PLC), resulting in inositol triphosphate (IP3)-dependent release of Ca 2 þ from intracellular stores and Ca 2 þ influx from extracellular sources. 26 Interference of the PLC-IP3 pathway thus ought to suppress the protection exerted by PDGF. As expected, pre-treatment of neurons with the PLC inhibitor U73122 (1 mM) did indeed abolish the neuroprotective action of PDGF against Tat toxicity, whereas its inactive analog U73343 (1 mM) did not exert this effect. The neuroprotective effect of PDGF also depended on IP3R activation, because exposure of neurons to antagonists specific for IP3 receptor, 2-ApB (100 mM) as well as Xest-C (1 mM), resulted in suppression of PDGF-mediated neuroprotection. Treatment of neurons with OAG (50 mM), a membrane permeable analog of diacylglycerol (DAG); however, did not protect rat primary midbrain neurons against Tat toxicity, suggesting thereby that PLC-DAG pathway was not involved in PDGF-mediated neuroprotection. Taken together, these findings confirmed the role of PLC-IP3R pathway in PDGF-mediated neuronal protection against Tat toxicity.
TRPC channels contribute to PDGF-induced intracellular Ca 2 þ elevations. To study the effects of PDGF on the intracellular Ca 2 þ transients (i) in rat primary midbrain neurons, we first measured PDGF-induced intracellular [Ca 2 þ ]i release using Fluo-4/AM imaging. As shown in Figure 4a and b, exposure of neurons to PDGF triggered a rapid and substantial [Ca 2 þ ]i increase in primary midbrain neurons. This response was inhibited by the PDGF receptor antagonist STI-571 ( Figure 4c ). Furthermore, this elevation in [Ca 2 þ ]i-induced by PDGF was suppressed by culturing cells in Ca 2 þ -free medium in the presence of EGTA (2 mM), suggesting thereby that PDGF-induced [Ca 2 þ ]i increase depended on the extracellular Ca 2 þ influx ( Figure 4c ).
As TRPC channels are Ca 2 þ -permeable cation channels, we next wanted to assess whether PDGF-induced [Ca 2 þ ]i elevations in primary midbrain neurons were mediated by TRPC. To confirm the role of TRPC in PDGF-induced [Ca 2 þ ]i elevations, rat midbrain neurons were pre-treated with the SKF96365 (20 mM) before treatment of the cells with PDGF. As shown in Figure 4c cells pre-treated with the SKF96365 showed marked reduction of PDGF-induced elevation of [Ca 2 þ ]i, thus underscoring the role of TPRC in this process. In contrast, the L-type voltage-gated calcium channel blocker nifedipine (10 mM) did not affect PDGF-induced [Ca 2 þ ]i elevation. Having determined the role of specific TRPC proteins in neuroprotection-mediated by PDGF, we next sought to dissect the role of specific TRPC channels in PDGF-induced Ca 2 þ influx. Similar to our findings of the role of TRPC 5 and 6 in PDGF-mediated neuroprotection, TRPC5 & 6 siRNA, but not TRPC 1 siRNA attenuated Ca 2 þ -influx induced by PDGF ( Figure 4d ).
As PDGF/PDGF-bR activation stimulates PLC, the next set of experiments was conducted using the PLC inhibitor U73122 (1 mM). Similar to findings with the SKF96365, neurons pre-treated with U73122, failed to show PDGF-induced [Ca 2 þ ]i elevation ( Figure 4c ). Interestingly, pre-treatment of neurons with the inactive analog of U73122 (U73343) had no effect on PDGF-induced Ca 2 þ influx. Furthermore, pre-treatment of neurons with the IP3R PDGF-mediated activation of TRPC channels involves amplification of the ERK signal via the Pyk2 pathway. ERK/mitogen-activated protein kinase (MAPK) pathway has been shown to have a crucial role in antiapoptotic mechanisms. It was therefore of interest to examine the effect of PDGF on ERK activation in rat primary neurons. As shown in Figure 5a , exposure of neurons to PDGF resulted in a sustained and time-dependent activation of ERK, which was partially inhibited by pre-treating cells with the PDGF-bR antagonist STI-571. PDGF-mediated ERK activation was completely abrogated by the MAPK/ ERK kinase (MEK) inhibitor U0126 (20 mM), but not by the PI3K inhibitor LY294002 (20 mM) ( Figure 5b ). The functional role of PDGF-induced ERK activation in mediating neuroprotection was also corroborated using cell viability assays, wherein PDGF failed to exert its protective effect in cells pre-treated with MEK inhibitor, thereby underscoring the role of this pathway in PDGF-mediated neuroprotection ( Figure 5c ). Activation of the ERK pathway is known to be mediated by an upstream signaling molecule -the Ca 2 þ -sensitive, prolinerich tyrosine kinase 2 (Pyk2). In our findings we demonstrated PDGF-mediated induction of Pyk2 as early as 5 mins following stimulation of the cells (Figure 5d ). In addition to Pyk2, CaMKs, another class of Ca 2 þ -sensitive signaling molecules are also known to have critical roles in cell survival. We thus sought to examine whether PDGF-mediated neuroprotection also involved activation of CaMKs. As shown in Figure 5e PDGF failed to activate either CaMK II or CaMKIV, thereby ruling out the role of these molecules in PDGF-mediated neuroprotection.
As CREB is a transcriptional factor that lies downstream of ERK and has an important role in cell survival, we next examined CREB phosphorylation following PDGF treatment using western blot analysis. As shown in Figure 5f , treatment of neurons with PDGF resulted in increased nuclear CREB phosphorylation that correlated well with a concomitant decrease in cytosolic CREB.
Having determined the role of TRPC channels in PDGFmediated neuroprotection we next wanted to dissect the role of these channels in PDGF-mediated ERK activation pathway. Pre-treatment of neurons with either the TRP channels blocker SKF96365 (20 mM) or EGTA (2 mM) markedly attenuated PDGF-induced phosphorylation of Pyk2, ERK and CREB (Figure 6a -c). These findings suggested that PDGFmediated neuroprotection via the TRPC/Ca 2 þ pathway involves phosphorylation of Pyk2, ERK and CREB-signaling molecules.
To further confirm the role of specific TRPC protein(s) in PDGF-induced ERK, Pyk2 and CREB phosphorylation, each of the TRPC subtypes (1, 5 or 6) was individually downregulated using specific siRNA followed by assessment of PDGF-induced ERK, Pyk2 and CREB phosphorylation. Interestingly, siRNA for both TRPC 5 and 6 decreased PDGF-mediated Pyk2, ERK and CREB phosphorylation ( TRPC channels are not required for PDGF-induced Akt activation. In addition to the MEK/ERK pathway, PI3K-Akt pathway also has a critical role in cell survival. We thus examined the role of the latter pathway in PDGF-mediated neuroprotection. As shown in Figure 8a , following exposure of neurons to PDGF there was an enhanced activation of Akt, which was abrogated by both the PDGF-bR antagonist STI-571 (1 mM) as well as the PI3 K inhibitor LY294002 (20 mM) ( Figure 8b ). We next wanted to assess the functional role of PI3K-Akt in PDGF-mediated neuroprotection against Tat. As shown in Figure 8c , PDGF pre-treatment resulted in the inhibition of Tat neurotoxicity and this effect was reversed in the presence of PI3K inhibitor LY294002. These results suggested the involvement of PI3K/Akt pathway in PDGF-mediated neuroprotection against HIV Tat. Further confirmation of the involvement of Akt pathway in PDGFmediated neuroprotection was shown with the use of adenovirus vector constructs encoding a dominantinterfering form of Akt. As shown in Figure 8d , in neurons infected with the dominant-interfering form of Akt, PDGF failed to protect against Tat toxicity. Infection of neurons with wild type Akt, on the other hand, resulted in PDGF-mediated neuroprotection as expected.
Having determined that TRPC channels were involved in regulation of ERK/CREB activation, we next wanted to dissect the role of these channels in PDGF-mediated Akt activation pathway. As shown in Figure 8e , pre-treatment of neurons with both the TRP channel blocker SKF96365 as well as EGTA did not attenuate PDGF-induced Akt activation. Furthermore, siRNA for TRPC (s) did not significantly decrease PDGF-mediated Akt phosphorylation (Figure 8f ). These findings thus suggested that PDGF-mediated Akt phosphorylation is independent of TRPC.
PDGF-mediated protection of dopaminergic neurons against HIV Tat in vivo. To investigate the relevance of PDGF-mediated protection in vivo, the neuroprotective effect of PDGF on dopaminergic neuronal survival was determined in adult mice injected intrastriatally with either saline or PDGF followed by microinjection with HIV-1 Tat. Seven days later mice brains were examined for TH-positive neurons in the substantia nigra. As shown in Figure 9a , there was increased Figure 9b , indicating that PDGF protected dopaminergic neurons against HIV Tat. Similar to saline-injected mice, exposure to PDGF alone had no significant effect on neuronal survival. Furthermore, to confirm the role of TRPC in PDGF-mediated neuroprotection against Tat, we pre-treated mice with the TRP channels blocker SKF96365 before treatment with PDGF and HIV Tat. Pre-treatment of mice with SKF96365 (0.2 mmol) followed by exposure to PDGF and Tat resulted in attenuation of PDGFmediated neuroprotection. Injection of the mice with the TRP channel blocker, SKF96365 alone did not exert any effect on the dopaminergic neurons. 
Discussion
In this study, we show that in vivo PDGF was able to rescue dopaminergic neurons from HIV Tat neurotoxicity. Confirmation of the neuroprotective role of PDGF against Tat toxicity was also corroborated in vitro in primary cultures of rat midbrain neurons. We showed a novel role of the Ca 2 þpermeable channel TRPC in PDGF-mediated neuroprotection in rat neurons, indicating that exogenous PDGF activated TRPC resulting in amplification of downstream ERK signaling via the Pyk2 pathway, followed by nuclear translocation of CREB and ultimately culminating in neuronal survival.
Nigrostriatal neurons are susceptible to HIV-1 proteinmediated toxicity and HIV Tat is known to inhibit TH gene expression in dopaminergic neurons contributing to motor abnormalities in HAD patients. 3 Expression of PDGF-bR in the dopaminergic neurons and its role in neuronal communication and possibly in dopaminergic neurotransmission circuitry has been shown by Othberg et.al. 16 In our studies, we detected the presence and activation of PDGF-bR in rat primary cultured midbrain neurons. In addition, using the pharmacological and siRNA approaches we also showed that PDGF-mediated neuroprotection involved activation of PDGF-bR.
A novel finding of this study is the role of TRPC in PDGFmediated neuroprotection against HIV Tat, thereby lending credence to previous reports indicating the involvement of TRPC signaling in neuroprotection. 17, 27 The mammalian TRPC channel family consists of seven members, TRPC1-7, that appear to function as receptor-operated channels, analogous to the TRP channels involved in Drosophilia phototransduction. 28 With the exception of TRPC2, these channels are widely distributed in the mammalian brain. Consistent with the previous reports showing the co-localiza-tion of TRPC (1,5 and 6) with the dopaminergic neurons in substantia nigra, [29] [30] [31] our findings also provide evidence that TRPC5/6 were colocalized with PDGF-bR in primary midbrain neurons. The mammalian TRPC channels can be activated by G-protein-coupled receptors and RTKs. 18, 21, 22 PDGF-bR belongs to the RTK family and is known to activate PLC, leading to hydrolysis of phosphatidylinositol-4,5-biphosphate into membrane-bound DAG and soluble IP3. Generation of IP3 results in IP3 receptor-mediated release of Ca 2 þ from intracellular stores as well as Ca 2 þ influx from outside the cell. 26 PDGF triggers [Ca 2 þ ]i transients in neuronal precursor cells, 32 however, how PDGF regulates [Ca 2 þ ]i remains unclear. Here, we report that PDGF induces [Ca 2 þ ]i elevation through engagement of the PDGF-bR because PDGF receptor antagonist was able to abolish PDGF-mediated [Ca 2 þ ]i elevations. Furthermore, the increase of [Ca 2 þ ]i induced by PDGF was primarily due to Ca 2 þ increase through the PLC/IP3-induced Ca 2 þ release and the TRPC channels. These findings were supported by a pharmacological approach using inhibitors specific for PLC (U73122), IP3R (2ApB and Xest-C) and TRP channels (SKF96365), all of which effectively blocked PDGF-mediated [Ca 2 þ ]i elevations. PDGF-mediated calcium influx from extracellular source was confirmed by EGTA, an extracellular Ca 2 þ chelator, which also blocked PDGF-mediated elevation of [Ca 2 þ ]i.
Influx of Ca 2 þ is known to regulate numerous physiological processes through a wide range of target proteins such as ERK, Pyk2 and CREB, [33] [34] [35] which are essential for neuronal survival. In fact, autophosphorylation of Pyk2 on the conserved tyrosine residues Y 402 36, 37 has been shown to result in downstream activation of ERK. In this study, we showed that [Ca 2 þ ]i elevations triggered by PDGF through the TRPC channels activated CREB through the Pyk2/ERK pathway. Consistent with the previous reports that ERK and its downstream effector CREB have a role in neuroprotection, [38] [39] [40] PDGF-mediated neuroprotection also involved activation of the ERK pathway.
The seven TRPC channels are divided into two groups based upon their homology and mechanisms of activation. This study showed that TRPC 5 and 6, but not TRPC1 were required for PDGF-mediated neuroprotection against Tat toxicity. Previous findings have shown the protective role of TRPC1 in MPTP-induced toxicity in SH-SY5Y cells. 31 Recent studies have shed light on the mechanisms underlying the activation of TRPC channels by a growth factor such as brainderived neurotrophic factor. 17 In this study, activation of TRPC3 and TRPC6 stimulated two signaling pathways: Ca 2 þ /Ras/MEK/ERK and Ca 2 þ /CaM/CaMK that converged on CREB activation. 17 Our findings also unravel the role of TRPC activation by yet another neurorprotective growth factor PDGF. The mechanism of protection by PDGF however, involved action of ERK as well as the PI3K/Akt pathways, an effect that is consistent with the previous reports showing that PDGF stimulates PI3K/ Akt pathways in various other cell types. [38] [39] [40] ERK pathway can be activated via the PI3K activation or independent of it, depending on the cell type. 41 In this study, PDGF-mediated neuroprotection via ERK activation was independent of PI3K pathway, because PI3K inhibitor failed to inhibit PDGFmediated ERK phosphorylation. Role of Akt pathway in the neuroprotective effects of PDGF was further confirmed using a dominant-interfering form of Akt. Unlike the TRPC-mediated activation of Pyk2/ERK/CREB, PDGF-mediated activation of Akt was independent of TRPC channel activation.
Consistent with the in vitro study showing the involvement of TRPC in PDGF-mediated neuroprotection, we found that pre-treatment of adult mice with PDGF also resulted in rescue of Tat-mediated dopaminergic neuronal loss in the substantia nigra. Interestingly, this effect was attenuated by injecting TRP channel blocker-SKF96365 directly into the striatum. This study for the first time shows that TRPC channels are involved in PDGF-mediated neuroprotection. These findings lend credence to the previously published reports indicating the role of TRPC channels in granule cell survival. 17 In summary, activation of the PDGF/PDGF-bR axis resulted in stimulation of PLC/IP3 R pathway leading to activation of TRPC channels, which in turn, resulted in elevation of [Ca 2 þ ]i transients, culminating in activation of Pyk2/ERK/CREB, but not PI3K/Akt pathway (as shown in Figure 10 ). PDGFmediated neuronal survival also involved the Pyk2/ERK/ CREB pathway as well as the parallel PI3K/Akt pathway. Taken together our findings suggest that although the two pathways involved in PDGF-mediated neuroprotection against Tat operate independent of each other, their combined actions are necessary for the observed neuroprotective effect of PDGF. A better understanding of these molecular pathways could be critical for the development of therapeutic strategies against HAD.
Materials and Methods
Animals. C57BL/6N mice were purchased from (Charles River Laboratories Inc., Wilmington, MA, USA). All the animals were housed under conditions of constant temperature and humidity on a 12-h light, 12-h dark cycle, with lights on at 0700 h. Food and water were available ad libitum. All animal procedures were performed according to the protocols approved by the Institutional Animal Care and Use Committee of the University of Kansas Medical Center.
Neuronal culture and treatment. Primary neurons were prepared as described earlier with a few modifications. 42 Briefly, midbrain tissues were dissected from embryonic day 13 to 14 Sprague-Dawley rats and dissociated with a mild mechanical trituration. Dissociated cells were seeded first in DMEM/F12 supplemented with 10% fetal bovine serum. After 1 day, the cultures were supplemented with serum-free neurobasal medium containing B27 (50:1), 2 mM glutamax supplemented with antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin). After 7 days, the initial plating cultures consisted of 90% neuronspecific nuclear protein immunoreactive neurons of which 3% were TH-positive neurons. Based upon our earlier studies, primary midbrain neurons were treated with PDGF (R & D system, Minneapolis, MN, USA; 20 ng/ml) and HIV-1 Tat (UK College of Medicine, Lexington, KY, USA; 14 nM) at pre-determined concentrations. Treatment of neurons with pharmacological inhibitors (STI-571:1 mM; SKF96365: 20 mM; EGTA: 2 mM; U73122: 1 mM; U73343: 1 mM; 2ApB: 100 mM; Xest-C: 1 mM; Nifedipine: 10 mM; U0126: 20 mM; LY294002: 20 mM) involved pre-treatment of cells with the respective inhibitors for 1 h followed by Tat and/or PDGF exposure.
Surgery and microinjection. Ten-week-old C57BL/6N mice were anesthetized with 2.5% isofluorane and placed in a stereotaxic apparatus for cannula implantation. Using the stereotaxic coordinates, AP þ 0.86 mm posterior, ML-1.8 mm lateral to midline, and DV À3.5 mm to bregma according to Franklin and Paxinos mouse brain atlas. A permanent 26-G stainless steel guide cannula (C315G; Plastics One, Roanoke, VA, USA) was implanted into the right striatum. The guide cannula was secured in place using gel adhesive and dental cement applied sequentially to the skull. A 33-G stainless steel dummy cannula was used to seal the guide cannula when not in use. After surgery the animals were housed individually to avoid damage to guide and dummy cannula.
Following striatal cannulation animals were allowed to recover for 7 days and were randomly divided into six groups (n ¼ 5): Saline, Tat, PDGF alone, PDGF plus Tat, and SKF96365 plus PDGF plus Tat (using two doses of the SKF96365 -see below) groups. Tat and PDGF each were injected at a concentration of 1 mg per 2 ml/ mouse/day for 2 days. Saline control mice were injected with the same volume of sterile saline (2 ml). In the PDGF plus Tat group of mice, PDGF was first microinjected for 2 days followed by HIV-1 Tat microinjection subsequently for 2 days. To determine the optimal dose of the TRP channel blocker in mice, SKF96365 freshly dissolved in 0.9% sterile saline, was injected at two different concentrations, (0.02 mmol and 0.2 mmol/2 ml/mouse; concentrations determined from our in vitro study) for 2 consecutive days, followed by PDGF and Tat microinjections. All microinjections were performed using a 33-G stainless steel injector connected to a 10 ml syringe, which was operated by an infusion pump set at the rate of 0.4 ml/min. An additional minute was allowed for diffusion and prevention of backflow through the needle track before the injector was withdrawn. Histological verification of the striatum cannula was performed at the end of each experiment.
Cell survival. The percentage of surviving neurons in the presence of PDGF and /or HIV-1 Tat was estimated using the biochemical and histological analyses listed below.
MTT. Cell viability was measured by mitochondrial dehydrogenases MTT method. Primary midbrain neurons were seeded in 96-well plates at a density of 10 5 cells per cm 2 for 7 days, following which neurons were exposed to fresh medium containing various concentrations of PDGF for 20 min at 37 1C. Subsequently, HIV-1 Tat (14 nM) was added into the medium and cells were incubated for another 24 h (concentration pre-determined from our previous work). 25 After incubation for up to 24 h, 20 ml MTT tetrazolium salt dissolved in Hank's balanced salt solution at a final concentration of 5 mg/ml was added to each well and incubated in the CO 2 incubator for 4 h. Finally, the medium was aspirated from each well and 200 ml of DMSO was added to dissolve the formazan crystals and the absorbance of each well was obtained using a Dynatech MR5000 plate counter at test and reference wavelengths of 570 and 630 nm, respectively.
Hoechst staining. To quantify apoptotic neurons, neurons were fixed and stained with Hoechst 33324 (Sigma, St Louis, MO, USA). The morphological features of apoptosis (cell shrinkage, chromatin condensation, and fragmentation) were monitored by fluorescence microscopy (Olympus BX 60, Tokyo, Japan). At least 400 cells from 12 randomly selected fields per dish were counted, and each treatment was performed in triplicate. [Ca 2 þ ]i elevation in turn results in activation of Pyk2/ERK pathways leading to CREB activation and consequently neuronal survival. In addition to this, PDGF/ PDGF-bR axis can also activate another distinct pathway -PI3K/Akt, which can also lead to potentiation of neuronal survival cells with intact membranes are distinguished by their ability to exclude propidium iodide, which readily penetrates dead or damaged cells. Dual analysis was introduced using a quadrant dot plot, in which necrotic cells were identified as single PI-positive, early apoptotic cells were Annexin V-FITC-positive only, and cells in late apoptosis were recognized as double-positive for annexin V-FITC and propidium iodide. Cells that stained negative for both annexin V-FITC and propidium iodide were classified as live cells. Finally, the number of cells in each category was expressed as a percentage of the total number of stained cells counted.
Analyses of neuronal dendrites. Primary rat midbrain neurons were stained with anti-MAP-2 antibody and dopaminergic neurons were identified with the anti-TH as described previously with minor modifications. 43 For the measurement of the dendrite length, images of individual MAP-2/TH-positive neurons were recorded. The length of each fiber originating from each neuronal cell body and subsequent branches was measured, and a sum of total dendrite length for each neuron was calculated using Image Pro-plus software. For each well, 50 neurons were analyzed for total dendrite length. Results were expressed as a percentage of the control cultures using a Nikon TE2000E microscope with a digital camera (Photometrics, Tucson, AZ, USA). 43 Measurement of [Ca 2 þ ]i . The changes in [Ca 2 þ ]i were monitored using Fluo-4/AM dissolved in dimethyl sulfoxide. The rat midbrain neurons in 35-mm culture dishes were rinsed twice with Physiological Solution (PS, 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 10 mM glucose, 5.5 mM HEPES, pH 7.4) followed by incubation in PS containing 5 mM Fluo-4/AM (Molecular Probes, Eugene, OR, USA) at 37 1C for 40 min. Cells were then rinsed twice with the PS, mounted on a perfusion chamber and scanned every second using confocal microscopy (Fluoview 300; Olympus). Fluorescence excitation at 488 nm was provided by an argon laser, and the emitted light (515 nm) captured along with transmitted images. All analyses of [Ca 2 þ ]i were processed at a single-cell level and are expressed as the relative fluorescence intensity. For ratiometric analysis, cells were loaded (using procedures described above) with Fluo-4 and Fura-Red. Fluorescence values from subcellular regions were calculated as mean pixel values±S.E., and a ratio was calculated by using the Fluo-4/Fura Red combination. All of these studies were done at least four times.
Western blotting. Treated cells were lysed using the Mammalian Cell Lysis kit (Sigma) and the NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce, Rockford, IL, USA). Equal amounts of the corresponding proteins were electrophoresed in a sodium dodecyl sulfate-polyacrylamide gel in reducing conditions followed by transfer to PVDF membranes. The blots were blocked with 5% non fat dry milk in phosphate-buffered saline. The western blots were then probed with antibodies recognizing the phosphorylated forms of PDGF-bR,ERK1/2, Pyk2, Akt, CREB (Cell Signaling, Danvers, MA, USA 1:200), and b-actin (Sigma, 1:4000) The secondary antibodies were alkaline phosphatase conjugated to goat anti-mouse/rabbit IgG (1:5000). Signals were detected by chemiluminescence (Pierce). All of western blot was repeated at least three times.
Coimmunoprecipitation. The procedure for immunoprecipitation was performed as described previously. 15 Briefly, rat primary neurons were treated with PDGF and/ or PDGF-receptor antagonist STI-571 or siRNAs followed by lysis in RIPA buffer (50 mm Tris, pH 8.0, 150 mm NaCl, 0.1% SDS, 1.0% NP-40 and 0.5% sodium deoxycholate) containing proteinase and phosphatase inhibitors. For each sample, 200 mg of protein was used for coimmunoprecipitation. The sample protein was incubated with 2 mg diluted anti-4-G-10 or Pyk2 antibody (Millipore, Billerica, MA, USA or Cell signaling) overnight at 41C followed by incubation with 20 ml of protein A-sepharose for 3 h at 41C. The mixture was then centrifuged (at 6000 g for 30 s) and the cell pellets were rinsed twice with RIPA, followed by boiling in 2 Â western blot loading buffer for 4 min. After spinning (at 6000 g for 30 s) the supernatants were subjected to western blot as described above.
Adenovirus infection. Primary midbrain neurons were infected with adenoviral constructs containing the WT or dominant-interfering forms of Akt (kind gift from Dr K Walsh). Neurons infected for 48 h with adenovirus constructs were subsequently treated with Tat and/or PDGF followed by assessment of cell survival as described above.
Short-interfering (si) RNA transfection. siRNA targeted against PDGF-bR were obtained from Thermo Scientific Dharmacon RNAi Technologies (Chicago, IL, USA; Accell SMART Pool, Cat no. E-091874-00). siRNAs targeted against TRPC1, 5 and 6 were obtained from Ambion (Austin, TX, USA). The sequences of these siRNAs are listed in Table 1 . For siRNA transfection, we used the rat Neuron Nucleofector Kit (Amaxa, Gaithersburg, MD, USA) according to the manufacturer's instructions. Briefly, dissociated cells were re-suspended in transfection medium, mixed with the respective siRNAs (200 nM), and electroporated using the fixed program (O-03) for optimal neuronal transfection. Cells were then quickly centrifuged, resuspended and plated. The knockdown efficiency of siRNAs was determined after 7 days of transfection by western blotting.
Immunochemistry. For immunocytochemistry primary midbrain neurons were plated on cover slips. After 7 days, cells were fixed with 4% paraformaldehyde for 15 min at room temperature followed by permeabilization with 0.3% Triton X-100 in PBS. Cells were then incubated with a blocking buffer containing 10% normal goat serum in PBS for 1 h at room temperature followed by addition of rabbit anti-TRPC 5 and 6 (1:100; Alomone Lab, Jerusalem, Israel) and mouse anti-PDGF-bR (1:500; Cell Signalling) antibodies and incubated overnight at 4 1C. Finally, the secondary AlexaFluor 488 goat anti-rabbit IgG and AlexaFluor 569 goat anti-mouse IgG, was added at a 1:500 dilution for 2 h to detect TRPC and PDGF-bR. Cells were washed three times in buffer and mounted with Vectashield onto slides (Vector Laboratories, Burlingame, CA, USA).Confocal images were taken at a magnification of Â 60(objective lens) with an Eclipse C1 Plus confocal microscope (Nikon).
For immunohistochemistry mice were perfused by transcardial perfusion using chilled 4% paraformaldehyde. Free-floating sections encompassing the entire midbrain were sectioned at 40 mm on a cryostat. For TH immunostaining, tissue sections were incubated with primary antibodies overnight at 4 1C. Primary antibodies used in this study were as follows: rabbit anti-TH (1:4000, Sigma). Immunostaining was visualized by using 3, 3-diaminobenzidine as the substrate. Quantitative (neuronal number) estimates of TH-positive cell bodies were performed ipsilaterally in the areas of interest using stereology method.
Statistical analysis. Data were expressed as mean±S.E.M. Significance of differences between control and samples treated with various drugs was determined by one-way ANOVA followed by post hoc least significant difference test. Values of Po0.05 were taken as statistically significant. 
